NASDAQ:OPTN OptiNose Q1 2023 Earnings Report $9.28 +0.02 (+0.22%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$9.28 0.00 (0.00%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast OptiNose EPS ResultsActual EPS-$2.55Consensus EPS -$2.40Beat/MissMissed by -$0.15One Year Ago EPSN/AOptiNose Revenue ResultsActual Revenue$11.85 millionExpected Revenue$10.30 millionBeat/MissBeat by +$1.55 millionYoY Revenue GrowthN/AOptiNose Announcement DetailsQuarterQ1 2023Date5/11/2023TimeN/AConference Call DateThursday, May 11, 2023Conference Call Time8:00AM ETUpcoming EarningsOptiNose's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 10:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by OptiNose Q1 2023 Earnings Call TranscriptProvided by QuartrMay 11, 2023 ShareLink copied to clipboard.There are 5 speakers on the call. Operator00:00:02Good day and thank you for standing by. Welcome to the OptiNose First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. You will then hear an automated message advising your hand is phrased. Operator00:00:26Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President, Investor Relations. Please go ahead. Speaker 100:00:37Good morning, and thank you for joining us today as we review OptiNose's Q1 2023 performance and our plans for the remainder of the year. I'm joined today by our CEO, Doctor. Rami Mahmoud and our Chief Commercial Officer, Paul Spence. The slides that will be presented on this call can be reviewed on our website, optiNose.com in the Before we start, I would like to remind you that our discussions during this conference call will include forward looking statements. All statements that are not historical facts are hereby identified Forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated by such statements. Speaker 100:01:11Additional information regarding these factors and forward looking statements is discussed under the cautionary note on forward looking statements section of the earnings release that we issued today as well as under the Risk Factors section and elsewhere in OptiNose's most recent Form 10 ks and 10 Qs that are filed with the SEC and available at their website at sec.gov and on our website atoptiNose.com. You are cautioned not to place undue reliance on forward looking statements. Forward looking statements during this conference call speak only as of the original date of this call or Any earlier date indicated in such statements, and we undertake no obligation to update or revise any of these statements. We will now make prepared remarks, and then we will move to a question and answer session. With that, I will now turn the call over to Rami. Speaker 200:01:50Great. Thank you, Jonathan, and thank you to everyone listening for joining us this morning. We appreciate you joining us for this Q1 update. Starting on Slide 3. We'll go into more detail in a moment, but I'd like to highlight 3 key takeaways from today's presentation. Speaker 200:02:05First, we remain enthusiastic about the potential value of a first and only new indication to treat patients who have chronic sinusitis. Claims data suggest that CS is currently being diagnosed by healthcare providers approximately 10 times more frequently than nasal polyps. In the current healthcare environment where off label use is increasingly constrained by payers, we believe the new indication could enable us to access a multifold larger patient audience and therefore drive significant growth. 2nd, last week we announced that the FDA accepted our supplemental new drug application for the new indication for XHANCE. In simple terms, the acceptance signals that a review of our application will proceed and that a goal date is set for December, by which the FDA will aim to communicate a decision. Speaker 200:02:533rd, in the Q1 of the year, we continued to execute against our previously communicated strategy To prioritize the value of a potential launch of XHANCE as the first ever FDA approved drug treatment for CS. There are important differences, including patient prevalence, frequency of diagnosis and payer dynamics that we believe make the And the return available from promotion of XHANCE as a treatment for nasal polyps. Because of this, as we advised in our last update, We've structured our business to reduce use of cash in 2023 and increase focus on profitability, while In the Q1, we adhered to the strategic intent and delivered results that met the expectations that we set in the previous call and which keep us on track to meet our expectations for the full year. Turning to Slide 4. We believe a future approval of XHANCE as the first and only FDA approved treatment for CS Has potential to increase the number of patients for whom the product can be promoted by tenfold because claims data suggest that that order of magnitude More patients are currently diagnosed and treated for chronic sinusitis than are diagnosed and treated for nasal polyps. Speaker 200:04:19We expect the greatly expanded universe of potential patients To include many who are currently cared for by physicians in our existing commercial footprint, significantly growing our potential within the scope of our current activities. We also expect the expanded universe of patients to include patients who are cared for by physicians outside of our current commercial reach. We are exploring commercial partnerships, alternative selling models and other ways to facilitate future outreach to those physicians and patients. Turning to Slide 6. Last week, we announced that the FDA accepted our supplemental new drug application in pursuit of an additional XHANCE indication for This is a novel indication for which the agency had never previously approved a product. Speaker 200:05:04Focusing on what's next, The acceptance marked the start of the substantive review of safety and efficacy. The FDA action goal date, which is based on the original submission date in February, has been set for mid December of this year. In the interim, our regulatory and clinical teams will focus on being responsive to the FDA during the review. Turning to Slide 8. In our Q1, the prescription demand results were aligned with the expectations that were set As a reminder, our objective in 2023 is to stabilize demand trends in our current business with a reduced commercial footprint, While preserving the necessary capabilities and creating an efficient deployment of resources to support a successful launch of XHANCE for CS in 2024. Speaker 200:05:55In the Q1 of 2023, there were approximately 30,400 new prescriptions for XHANCE, an increase of 3% While the market which is defined by INS prescriptions written by any physician for any condition, A quite large component of which are prescriptions for allergic rhinitis increased 8% over the same period. In addition, there were 84,400 total prescriptions for XHANCE in the Q1 of 2023, an increase of 1% Compared to Q1 2022, while the market, which again includes INS prescriptions written by any physician for any condition, a large component of which are prescriptions for allergic rhinitis increased 5% over the same period. Results were mixed For breadth and depth of physician prescribing as measured by the total number of physicians who have patients filling XHANCE prescriptions. Regarding breadth, in the Q1 of 2023, there were 8,545 physicians who had a patient fill at least one prescription for XHANCE, a decrease of 1% from Q1 2022 to Q1 2023. I'd like to note All the data on this slide is estimated based on monthly prescription data from third parties and in large part also on data directly reported to us by pharmacies that are part of the XHANCE preferred pharmacy network. Speaker 200:07:33I will note that the Q1 2022 data we're showing today reflects our current 2023 methodology. For reference, we've footnoted our prior estimates based on prior methodology. While our best estimates may indicate slight growth in prescription demand, We believe stable is an appropriate way to describe these results. I'll now turn the call over to Jonathan to discuss our Q1 financial performance. Speaker 100:07:57Thank you, Rami. Turning to Slide 10. Our Q1 2023 financial results are largely in line with the expectations we communicated on our last earnings call And are shaped by our strategy to prioritize capital resources for the potential launch of XHANCE as the first ever FDA approved drug treatment for chronic sinusitis. As we reported this morning, OptiNose recognized $24,500,000 of SG and A plus R and D expenses in the Q1 of 2023, Approximately a $10,000,000 decrease compared to Q1 2022 expenses of $34,100,000 Regarding revenue, OptiNose recognized $11,800,000 of Exant's net revenue in the Q1 of 2023, a decrease compared to Q1 2022 net revenues of $14,800,000 Year over year decrease in the Q1 is primarily the result of a decrease in unit shift and an increase in co pay assistance driven by An increase in the proportion of volumes attributable to patients with commercial insurance that does not cover XHANCE or who have not yet met the utilization management criteria of their insurer, as well as an increase in the proportion of volumes attributable to government programs, which increased gross to net deductions. While we exceeded the Q1 2023 Guidance that we gave on our last call for revenues of approximately $10,000,000 in the Q1, and we feel that the beat is encouraging, I'd like to note that we believe this result is not sufficient to change our expectations for the full year, which I will review in a moment. Speaker 100:09:20Finally, based on available prescription data purchased from 3rd parties and on data we received directly from our preferred pharmacy network, the estimated Xantzen's average net revenue prescription for Q1 of 2023 was $140 a decrease compared to $177 of estimated revenue per prescription in the Q1 of 2022. Year over year decrease is driven primarily by the increase in gross to net deductions and the decrease in units shipped that influenced XHANCE net revenue performance. Overall, these results align with our intent to reduce use of cash in 2023, Maintaining the capabilities and resources that will be necessary to enable a successful launch in a new indication of toraxant in 2024. Turning to Slide 12. Our Q1 2023 financial performance was in line with our prior guidance and as a result, our guidance for the full year of 2023 is largely unchanged. Speaker 100:10:13First, we are lowering our operating expense guidance to incorporate the effects of 1st quarter departures on stock compensation. We now expect operating expense to be in the range from $88,000,000 to $93,000,000 of which approximately $6,000,000 of stock based compensation. Previously, we expected operating to be in the range from $90,000,000 to $95,000,000 of which approximately $8,000,000 is stock based compensation. 2nd, our expectation for XHANCE net revenue for the full year of 2023 is unchanged and is between $62,000,000 to $68,000,000 It It is important to note that we are not assuming revenues from a CS launch in our full year 2023 guidance. 3rd, with respect to XHANCE average net revenue per prescription, We expect our typical historical pattern of improvement from the Q1 through the remaining three quarters of 2023 and continue to expect our average net revenue I will now turn the call back over to Rami for closing remarks. Speaker 100:11:19Rami? Speaker 200:11:20Thank you, Jonathan. Before moving to Q and A, I'd like to take a moment to reiterate our clear strategic focus for this year. First, we believe achieving the first ever chronic sinusitis indication will be a crucial driver of future value for patients and for our company. It is therefore our top priority. 2nd, we are mindful of the importance of the cash we have today and of the potentially greater value of commercial investment following future potential CS indication. Speaker 200:11:48Therefore, we have taken and will continue to take action to efficiently generate XHANCE revenue with the current indication. 3rd, we must prepare our organization to seize the potential opportunity created by a new chronic sinusitis indication With that, I'd like to thank you for your attention and open the call for questions and answers. Operator00:12:15Thank you. Our first question comes from the line of Brandon Folkes with Cantor Fitzgerald. Your line is now open. Speaker 300:12:38Hi, thanks for taking my questions and congratulations on the quarter. Maybe just 2 for me. With that prescribing breadth growing, are these new prescribers asking questions about the CS indication? I guess any color Well, how would you contextualize how prime the market is for CS launch, understanding obviously you're not promoting CS right now. So just any color on the awareness of the CS potential approval and the awareness in the prescribing community versus how much So the work would need to be done post approval. Speaker 300:13:14And then maybe just secondly, any color on how the 140 Net revenue per Rx compares to your expectations for 1Q given the guidance. Thank you. Speaker 200:13:25I'll take the first part of that Jonathan and then turn So with regard to prescriber expectations, I think we would characterize the change in prescriber breadth As relative stability compared to the previous year, rather than sort of a material growth, It is true that anecdotally we do get occasional questions about the chronic sinusitis future indication And we do occasionally get questions, of course, about the clinical trials, which have been completed, and which are pending publication in the peer reviewed literature. But by and large, the bulk of the prescribing universe is not yet aware of the chronic sinusitis indication in clinical trial data. And The investment that we will make in sort of making the prescribing universe aware of that is still Speaker 100:14:16to come. So then Brandon, on the second question regarding the $140 on revenue per prescription and how that compared to our expectations. I think we didn't set an explicit expectation for revenue per TRx in the Q1. We did set an expectation for Approximately $10,000,000 in XHANCE net revenues for the period. But I think that the $140 was aligned with our thinking about how the As a reminder, the last couple of years, what we anticipated at the start of the year, I think 2021 2022, we First quarter revenues to be, I think, 130 to 150 the 1 year, 140 to 160 the next year. Speaker 100:15:02And I think given our expectations around there being a little bit more aggressive management of inventory, Quicker return to kind of summer levels. This year because of the rising interest rate environment, yes, I think that $140,000,000 is best described as being in line with our expectations. Speaker 300:15:23Thank you to you both. Maybe just one follow-up, if I may. Any change in how we should think about the seasonality this year of XHANCE prescriptions? Speaker 200:15:34Yes, Brandon, thank you for asking that. I don't think we have sufficient evidence at this point in the year To believe there will be a material change in sort of the historical cadence of our revenue over the course of the year. As we noted earlier, the Q1 is traditionally light on revenue, although the prescription demand isn't Proportionately light because as you were discussing, it's related in large part to changes in the average net revenue per prescription. And then we have historically seen significant increase in 2nd quarter, bit of a nadir in 3rd quarter, bit of a softening maybe in 3rd quarter, especially during the summer and then sort of stronger performance in the latter part of the year. So I don't expect the pattern to change from historical trends. Speaker 300:16:27Thanks for taking my question. Yes. Speaker 100:16:29It's all I'll add in. I think Ravi speaking, I think largely to the demand Factors around seasonality. Yes, I think in terms of the cadence on revenue per prescription is patients Yes. The primary driver there being as patients fill their out of pocket minimums in the early part of the year, what we typically see is, Yes. 1st quarter is kind of the low point on revenue per prescription, strong return to something that looks like our past Our average for the year and Q2 and we sort of maintain that for the remainder of the year with a little bit of pressure at the year end to accrue for channel inventory Liabilities. Speaker 100:17:08So, I think our historical experience is how we're thinking about, how revenue should progress for the year. Speaker 300:17:17Great. Thank you for the color and congrats on the progress. Speaker 100:17:20Thanks, Manny. Operator00:17:22Thank you. Our next question comes from the line of David Amsellem with Piper Sandler. Your line is now open. Speaker 400:17:29Hi, thanks. This is Skyler on for David. Can you talk about what kind of dialogue, if any, you've had with payers regarding the CS data and how you think the payer landscape will evolve with the wider label in place? Do you expect that we will see a significant shift in the payer landscape after the label expansion? Speaker 200:17:47Hi, and thank you for the question. It's a little premature for us to have confidence in exactly how that will shape up. And of course, we can't speak in advance to decisions that haven't yet been made by different payers. But we're beginning really and have been for a little while now to approach this issue with various payers. And as we've said before, in many of our payer contracts, the existing language already accounts For all FDA approved indications, of course, today that refers only to the indication of chronic rhinosinusitis with nasal polyps, but in future that would encompass A new approval for a new indication. Speaker 200:18:27So we have reasonable confidence that we'll have stability in our payer coverage, But we can't be certain, until we get closer to the actual launch date and see how decisions pan out. Speaker 400:18:40Got it. So then a quick follow-up. For the net revenue per prescription, do you think that might evolve in the context of the wider label with CS? Speaker 200:18:51I don't think we have any reason to believe that our net revenue per prescription will be materially impacted By the new indication, the primary effect that we expect from the new indication is the ability to access a much, much larger patient population within a similar number of physicians that are in our current called on universe and then hopefully our ability to access the incremental patients in outside our current called on universe by another mechanism. Speaker 400:19:18And if I could just ask one more. What would the sales force headcount look like if you did or didn't have the co promote partner in place In terms of expanding to CS, do you expect a big increase in headcount? Speaker 200:19:32I can tell you that Today, we have 77 sales territories. I can't really speak to the number of sales territories that we would expect to have In the context of a primary care promotional partner, because that may vary depending on what kind of primary care promotional partner we've engaged with. So, it's sort of a TBD at this point. Speaker 400:19:55All right. Got it. Thanks for the color. Operator00:19:58Thank you. And I'm currently showing no further questions at this time. I'd like to hand the call back over to Rami Mahmoud for closing remarks. Speaker 200:20:07In conclusion, I think we have shown you information today reflecting Q1 performance that's entirely in line with We have the first and we intend to continue to meet the expectations that we've set as we progress onward through this year with a sense of optimism about the future approval as we enter into next year. Thank you again for joining this morning and we look forward to speaking with you again in a few more months. Operator00:20:31This concludes today's conference call. Thank you for participating. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallOptiNose Q1 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) OptiNose Earnings HeadlinesOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 26, 2025 | Porter & Company (Ad)Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comSee More OptiNose Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OptiNose? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiNose and other key companies, straight to your email. Email Address About OptiNoseOptiNose (NASDAQ:OPTN), a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.View OptiNose ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 5 speakers on the call. Operator00:00:02Good day and thank you for standing by. Welcome to the OptiNose First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. You will then hear an automated message advising your hand is phrased. Operator00:00:26Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President, Investor Relations. Please go ahead. Speaker 100:00:37Good morning, and thank you for joining us today as we review OptiNose's Q1 2023 performance and our plans for the remainder of the year. I'm joined today by our CEO, Doctor. Rami Mahmoud and our Chief Commercial Officer, Paul Spence. The slides that will be presented on this call can be reviewed on our website, optiNose.com in the Before we start, I would like to remind you that our discussions during this conference call will include forward looking statements. All statements that are not historical facts are hereby identified Forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated by such statements. Speaker 100:01:11Additional information regarding these factors and forward looking statements is discussed under the cautionary note on forward looking statements section of the earnings release that we issued today as well as under the Risk Factors section and elsewhere in OptiNose's most recent Form 10 ks and 10 Qs that are filed with the SEC and available at their website at sec.gov and on our website atoptiNose.com. You are cautioned not to place undue reliance on forward looking statements. Forward looking statements during this conference call speak only as of the original date of this call or Any earlier date indicated in such statements, and we undertake no obligation to update or revise any of these statements. We will now make prepared remarks, and then we will move to a question and answer session. With that, I will now turn the call over to Rami. Speaker 200:01:50Great. Thank you, Jonathan, and thank you to everyone listening for joining us this morning. We appreciate you joining us for this Q1 update. Starting on Slide 3. We'll go into more detail in a moment, but I'd like to highlight 3 key takeaways from today's presentation. Speaker 200:02:05First, we remain enthusiastic about the potential value of a first and only new indication to treat patients who have chronic sinusitis. Claims data suggest that CS is currently being diagnosed by healthcare providers approximately 10 times more frequently than nasal polyps. In the current healthcare environment where off label use is increasingly constrained by payers, we believe the new indication could enable us to access a multifold larger patient audience and therefore drive significant growth. 2nd, last week we announced that the FDA accepted our supplemental new drug application for the new indication for XHANCE. In simple terms, the acceptance signals that a review of our application will proceed and that a goal date is set for December, by which the FDA will aim to communicate a decision. Speaker 200:02:533rd, in the Q1 of the year, we continued to execute against our previously communicated strategy To prioritize the value of a potential launch of XHANCE as the first ever FDA approved drug treatment for CS. There are important differences, including patient prevalence, frequency of diagnosis and payer dynamics that we believe make the And the return available from promotion of XHANCE as a treatment for nasal polyps. Because of this, as we advised in our last update, We've structured our business to reduce use of cash in 2023 and increase focus on profitability, while In the Q1, we adhered to the strategic intent and delivered results that met the expectations that we set in the previous call and which keep us on track to meet our expectations for the full year. Turning to Slide 4. We believe a future approval of XHANCE as the first and only FDA approved treatment for CS Has potential to increase the number of patients for whom the product can be promoted by tenfold because claims data suggest that that order of magnitude More patients are currently diagnosed and treated for chronic sinusitis than are diagnosed and treated for nasal polyps. Speaker 200:04:19We expect the greatly expanded universe of potential patients To include many who are currently cared for by physicians in our existing commercial footprint, significantly growing our potential within the scope of our current activities. We also expect the expanded universe of patients to include patients who are cared for by physicians outside of our current commercial reach. We are exploring commercial partnerships, alternative selling models and other ways to facilitate future outreach to those physicians and patients. Turning to Slide 6. Last week, we announced that the FDA accepted our supplemental new drug application in pursuit of an additional XHANCE indication for This is a novel indication for which the agency had never previously approved a product. Speaker 200:05:04Focusing on what's next, The acceptance marked the start of the substantive review of safety and efficacy. The FDA action goal date, which is based on the original submission date in February, has been set for mid December of this year. In the interim, our regulatory and clinical teams will focus on being responsive to the FDA during the review. Turning to Slide 8. In our Q1, the prescription demand results were aligned with the expectations that were set As a reminder, our objective in 2023 is to stabilize demand trends in our current business with a reduced commercial footprint, While preserving the necessary capabilities and creating an efficient deployment of resources to support a successful launch of XHANCE for CS in 2024. Speaker 200:05:55In the Q1 of 2023, there were approximately 30,400 new prescriptions for XHANCE, an increase of 3% While the market which is defined by INS prescriptions written by any physician for any condition, A quite large component of which are prescriptions for allergic rhinitis increased 8% over the same period. In addition, there were 84,400 total prescriptions for XHANCE in the Q1 of 2023, an increase of 1% Compared to Q1 2022, while the market, which again includes INS prescriptions written by any physician for any condition, a large component of which are prescriptions for allergic rhinitis increased 5% over the same period. Results were mixed For breadth and depth of physician prescribing as measured by the total number of physicians who have patients filling XHANCE prescriptions. Regarding breadth, in the Q1 of 2023, there were 8,545 physicians who had a patient fill at least one prescription for XHANCE, a decrease of 1% from Q1 2022 to Q1 2023. I'd like to note All the data on this slide is estimated based on monthly prescription data from third parties and in large part also on data directly reported to us by pharmacies that are part of the XHANCE preferred pharmacy network. Speaker 200:07:33I will note that the Q1 2022 data we're showing today reflects our current 2023 methodology. For reference, we've footnoted our prior estimates based on prior methodology. While our best estimates may indicate slight growth in prescription demand, We believe stable is an appropriate way to describe these results. I'll now turn the call over to Jonathan to discuss our Q1 financial performance. Speaker 100:07:57Thank you, Rami. Turning to Slide 10. Our Q1 2023 financial results are largely in line with the expectations we communicated on our last earnings call And are shaped by our strategy to prioritize capital resources for the potential launch of XHANCE as the first ever FDA approved drug treatment for chronic sinusitis. As we reported this morning, OptiNose recognized $24,500,000 of SG and A plus R and D expenses in the Q1 of 2023, Approximately a $10,000,000 decrease compared to Q1 2022 expenses of $34,100,000 Regarding revenue, OptiNose recognized $11,800,000 of Exant's net revenue in the Q1 of 2023, a decrease compared to Q1 2022 net revenues of $14,800,000 Year over year decrease in the Q1 is primarily the result of a decrease in unit shift and an increase in co pay assistance driven by An increase in the proportion of volumes attributable to patients with commercial insurance that does not cover XHANCE or who have not yet met the utilization management criteria of their insurer, as well as an increase in the proportion of volumes attributable to government programs, which increased gross to net deductions. While we exceeded the Q1 2023 Guidance that we gave on our last call for revenues of approximately $10,000,000 in the Q1, and we feel that the beat is encouraging, I'd like to note that we believe this result is not sufficient to change our expectations for the full year, which I will review in a moment. Speaker 100:09:20Finally, based on available prescription data purchased from 3rd parties and on data we received directly from our preferred pharmacy network, the estimated Xantzen's average net revenue prescription for Q1 of 2023 was $140 a decrease compared to $177 of estimated revenue per prescription in the Q1 of 2022. Year over year decrease is driven primarily by the increase in gross to net deductions and the decrease in units shipped that influenced XHANCE net revenue performance. Overall, these results align with our intent to reduce use of cash in 2023, Maintaining the capabilities and resources that will be necessary to enable a successful launch in a new indication of toraxant in 2024. Turning to Slide 12. Our Q1 2023 financial performance was in line with our prior guidance and as a result, our guidance for the full year of 2023 is largely unchanged. Speaker 100:10:13First, we are lowering our operating expense guidance to incorporate the effects of 1st quarter departures on stock compensation. We now expect operating expense to be in the range from $88,000,000 to $93,000,000 of which approximately $6,000,000 of stock based compensation. Previously, we expected operating to be in the range from $90,000,000 to $95,000,000 of which approximately $8,000,000 is stock based compensation. 2nd, our expectation for XHANCE net revenue for the full year of 2023 is unchanged and is between $62,000,000 to $68,000,000 It It is important to note that we are not assuming revenues from a CS launch in our full year 2023 guidance. 3rd, with respect to XHANCE average net revenue per prescription, We expect our typical historical pattern of improvement from the Q1 through the remaining three quarters of 2023 and continue to expect our average net revenue I will now turn the call back over to Rami for closing remarks. Speaker 100:11:19Rami? Speaker 200:11:20Thank you, Jonathan. Before moving to Q and A, I'd like to take a moment to reiterate our clear strategic focus for this year. First, we believe achieving the first ever chronic sinusitis indication will be a crucial driver of future value for patients and for our company. It is therefore our top priority. 2nd, we are mindful of the importance of the cash we have today and of the potentially greater value of commercial investment following future potential CS indication. Speaker 200:11:48Therefore, we have taken and will continue to take action to efficiently generate XHANCE revenue with the current indication. 3rd, we must prepare our organization to seize the potential opportunity created by a new chronic sinusitis indication With that, I'd like to thank you for your attention and open the call for questions and answers. Operator00:12:15Thank you. Our first question comes from the line of Brandon Folkes with Cantor Fitzgerald. Your line is now open. Speaker 300:12:38Hi, thanks for taking my questions and congratulations on the quarter. Maybe just 2 for me. With that prescribing breadth growing, are these new prescribers asking questions about the CS indication? I guess any color Well, how would you contextualize how prime the market is for CS launch, understanding obviously you're not promoting CS right now. So just any color on the awareness of the CS potential approval and the awareness in the prescribing community versus how much So the work would need to be done post approval. Speaker 300:13:14And then maybe just secondly, any color on how the 140 Net revenue per Rx compares to your expectations for 1Q given the guidance. Thank you. Speaker 200:13:25I'll take the first part of that Jonathan and then turn So with regard to prescriber expectations, I think we would characterize the change in prescriber breadth As relative stability compared to the previous year, rather than sort of a material growth, It is true that anecdotally we do get occasional questions about the chronic sinusitis future indication And we do occasionally get questions, of course, about the clinical trials, which have been completed, and which are pending publication in the peer reviewed literature. But by and large, the bulk of the prescribing universe is not yet aware of the chronic sinusitis indication in clinical trial data. And The investment that we will make in sort of making the prescribing universe aware of that is still Speaker 100:14:16to come. So then Brandon, on the second question regarding the $140 on revenue per prescription and how that compared to our expectations. I think we didn't set an explicit expectation for revenue per TRx in the Q1. We did set an expectation for Approximately $10,000,000 in XHANCE net revenues for the period. But I think that the $140 was aligned with our thinking about how the As a reminder, the last couple of years, what we anticipated at the start of the year, I think 2021 2022, we First quarter revenues to be, I think, 130 to 150 the 1 year, 140 to 160 the next year. Speaker 100:15:02And I think given our expectations around there being a little bit more aggressive management of inventory, Quicker return to kind of summer levels. This year because of the rising interest rate environment, yes, I think that $140,000,000 is best described as being in line with our expectations. Speaker 300:15:23Thank you to you both. Maybe just one follow-up, if I may. Any change in how we should think about the seasonality this year of XHANCE prescriptions? Speaker 200:15:34Yes, Brandon, thank you for asking that. I don't think we have sufficient evidence at this point in the year To believe there will be a material change in sort of the historical cadence of our revenue over the course of the year. As we noted earlier, the Q1 is traditionally light on revenue, although the prescription demand isn't Proportionately light because as you were discussing, it's related in large part to changes in the average net revenue per prescription. And then we have historically seen significant increase in 2nd quarter, bit of a nadir in 3rd quarter, bit of a softening maybe in 3rd quarter, especially during the summer and then sort of stronger performance in the latter part of the year. So I don't expect the pattern to change from historical trends. Speaker 300:16:27Thanks for taking my question. Yes. Speaker 100:16:29It's all I'll add in. I think Ravi speaking, I think largely to the demand Factors around seasonality. Yes, I think in terms of the cadence on revenue per prescription is patients Yes. The primary driver there being as patients fill their out of pocket minimums in the early part of the year, what we typically see is, Yes. 1st quarter is kind of the low point on revenue per prescription, strong return to something that looks like our past Our average for the year and Q2 and we sort of maintain that for the remainder of the year with a little bit of pressure at the year end to accrue for channel inventory Liabilities. Speaker 100:17:08So, I think our historical experience is how we're thinking about, how revenue should progress for the year. Speaker 300:17:17Great. Thank you for the color and congrats on the progress. Speaker 100:17:20Thanks, Manny. Operator00:17:22Thank you. Our next question comes from the line of David Amsellem with Piper Sandler. Your line is now open. Speaker 400:17:29Hi, thanks. This is Skyler on for David. Can you talk about what kind of dialogue, if any, you've had with payers regarding the CS data and how you think the payer landscape will evolve with the wider label in place? Do you expect that we will see a significant shift in the payer landscape after the label expansion? Speaker 200:17:47Hi, and thank you for the question. It's a little premature for us to have confidence in exactly how that will shape up. And of course, we can't speak in advance to decisions that haven't yet been made by different payers. But we're beginning really and have been for a little while now to approach this issue with various payers. And as we've said before, in many of our payer contracts, the existing language already accounts For all FDA approved indications, of course, today that refers only to the indication of chronic rhinosinusitis with nasal polyps, but in future that would encompass A new approval for a new indication. Speaker 200:18:27So we have reasonable confidence that we'll have stability in our payer coverage, But we can't be certain, until we get closer to the actual launch date and see how decisions pan out. Speaker 400:18:40Got it. So then a quick follow-up. For the net revenue per prescription, do you think that might evolve in the context of the wider label with CS? Speaker 200:18:51I don't think we have any reason to believe that our net revenue per prescription will be materially impacted By the new indication, the primary effect that we expect from the new indication is the ability to access a much, much larger patient population within a similar number of physicians that are in our current called on universe and then hopefully our ability to access the incremental patients in outside our current called on universe by another mechanism. Speaker 400:19:18And if I could just ask one more. What would the sales force headcount look like if you did or didn't have the co promote partner in place In terms of expanding to CS, do you expect a big increase in headcount? Speaker 200:19:32I can tell you that Today, we have 77 sales territories. I can't really speak to the number of sales territories that we would expect to have In the context of a primary care promotional partner, because that may vary depending on what kind of primary care promotional partner we've engaged with. So, it's sort of a TBD at this point. Speaker 400:19:55All right. Got it. Thanks for the color. Operator00:19:58Thank you. And I'm currently showing no further questions at this time. I'd like to hand the call back over to Rami Mahmoud for closing remarks. Speaker 200:20:07In conclusion, I think we have shown you information today reflecting Q1 performance that's entirely in line with We have the first and we intend to continue to meet the expectations that we've set as we progress onward through this year with a sense of optimism about the future approval as we enter into next year. Thank you again for joining this morning and we look forward to speaking with you again in a few more months. Operator00:20:31This concludes today's conference call. Thank you for participating. You may now disconnect.Read morePowered by